St. Renatus

About St. Renatus

St. Renatus, LLC is a privately held life sciences company headquartered in Fort Collins, Colorado, operating within the dental pharmaceutical market. The company's inception traces back to the work of its founder, Dr. Mark Kollar, an endodontist with a background in biochemistry and molecular biology from the University of Minnesota. Dr. Kollar's professional experience treating patients who suffered from dental phobia, particularly a fear of needles, directly fueled the company's direction. To address this, St. Renatus, named after the patron saint of anesthesia, embarked on a mission to develop a less invasive alternative to traditional dental injections.

The culmination of their research and development efforts is Kovanaze®, a needle-free dental anesthetic administered as a nasal spray. This product received FDA approval in 2016, marking a significant milestone for the company. Kovanaze is specifically indicated for providing regional anesthesia for restorative procedures on teeth in the upper jaw, from the second premolar forward. The business model centers on the sale of Kovanaze to dental practices. St. Renatus markets this product as a way for dentists to enhance the patient experience by eliminating the pain and anxiety associated with needle-based anesthesia, thereby potentially improving patient satisfaction and practice efficiency.

The core of St. Renatus's value proposition lies in its single commercialized product, which combines tetracaine (a local anesthetic) and oxymetazoline (a vasoconstrictor) into a formulation that can be absorbed through the nasal passages to numb the upper teeth. The company primarily targets general dentists and specialists who are looking to differentiate their services and cater to anxious patients. The journey from concept to an FDA-approved product highlights the company's focus on addressing a specific, long-standing challenge in dental care through a novel drug delivery system.